Search results
4 days ago · July 2, 2024. Becton, Dickinson and Company ( NYSE:BDX - Get Free Report) had its target price dropped by Evercore ISI from $290.00 to $285.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an "outperform" rating on the medical instruments supplier's stock. Evercore ISI's price target points to a potential ...
23 hours ago · Barclays upped their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th.
23 hours ago · Evercore ISI lowered their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday.
1 day ago · About BDX. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
3 days ago · Enhance medication availability while increasing security and control of medications and supplies with a comprehensive system of automated dispensing solutions and pharmacy technologies across your healthcare system.
3 days ago · Becton, Dickinson and Company ( NYSE:BDX - Get Free Report) saw a large decline in short interest in June. As of June 15th, there was short interest totalling 1,970,000 shares, a decline of 11.7% from the May 31st total of 2,230,000 shares. Based on an average trading volume of 1,410,000 shares, the days-to-cover ratio is currently 1.4 days.
2 days ago · Company Info. Financial Info. Stock Data. SEC Filings. ESG. Governance. By reading this content you are acknowledging our forward looking statement. Email Alerts. Contacts.
